[go: up one dir, main page]

BRPI0407301A - Use of a combination, pharmaceutical composition, kit, and method for treating cancer in a warm-blooded animal such as a human. - Google Patents

Use of a combination, pharmaceutical composition, kit, and method for treating cancer in a warm-blooded animal such as a human.

Info

Publication number
BRPI0407301A
BRPI0407301A BR0407301-0A BRPI0407301A BRPI0407301A BR PI0407301 A BRPI0407301 A BR PI0407301A BR PI0407301 A BRPI0407301 A BR PI0407301A BR PI0407301 A BRPI0407301 A BR PI0407301A
Authority
BR
Brazil
Prior art keywords
cpt
human
combination
warm
kit
Prior art date
Application number
BR0407301-0A
Other languages
Portuguese (pt)
Inventor
Stephen Robert Wedge
Anderson Joseph Ryan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0303289A external-priority patent/GB0303289D0/en
Priority claimed from GB0314100A external-priority patent/GB0314100D0/en
Priority claimed from GB0316184A external-priority patent/GB0316184D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority claimed from PCT/GB2004/000550 external-priority patent/WO2004071397A2/en
Publication of BRPI0407301A publication Critical patent/BRPI0407301A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"USO DE UMA COMBINAçãO, COMPOSIçãO FARMACêUTICA, KIT, E, MéTODO PARA O TRATAMENTO DE CâNCER EM UM ANIMAL DE SANGUE QUENTE TAL COMO UM SER HUMANO". A presente invenção diz respeito a um método para a produção de um efeito de redução antiangiogênica e/ou de permeabilidade vascular em um animal de sangue quente tal como um ser humano, que opcionalmente está sendo tratado com radiação ionizante, particularmente um método para o tratamento de um câncer, particularmente um câncer envolvendo um tumor sólido, que compreende um de: a administração de ZD6474 em combinação com 5-FU; a administração de ZD6474 em combinação com CPT- 11; e a administração de ZD6474 em combinação com 5-FU e CPT-11; a uma composição farmacêutica compreendendo um de: ZD6474 e 5-FU; ZD6474 e CPT-11; e ZD6474 e 5-FU e CPT-11; a um produto combinado compreendendo um de: ZD6474 e 5-FU; ZD6474 e CPT-11; e ZD6474 e 5FU e CPT- 11, para o uso em um método de tratamento de um corpo humano ou animal por terapia; a um kit compreendendo um de: ZD6474 e 5-FU; ZD6474 e CPT-11; e ZD6474 e 5-FU e CPT-11; para o uso de um de: ZD6474 e 5-FU; ZD6474 e CPT-11; e ZD6474 e 5-FU e CPT-11, na fabricação de um medicamento para o uso na produção de um efeito de redução antiangiogênica e/ou de permeabilidade vascular em um animal de sangue quente tal como um ser humano que opcionalmente está sendo tratado com radiação ionizante."USE OF A COMBINATION, PHARMACEUTICAL COMPOSITION, KIT, AND METHOD FOR TREATMENT OF CANCER IN A HOT BLOOD ANIMAL LIKE A HUMAN". The present invention relates to a method for producing an antiangiogenic reducing and / or vascular permeability effect in a warm-blooded animal such as a human being, which is optionally being treated with ionizing radiation, particularly a method for treating from a cancer, particularly a cancer involving a solid tumor, comprising one of: administering ZD6474 in combination with 5-FU; administration of ZD6474 in combination with CPT-11; and administering ZD6474 in combination with 5-FU and CPT-11; a pharmaceutical composition comprising one of: ZD6474 and 5-FU; ZD6474 and CPT-11; and ZD6474 and 5-FU and CPT-11; to a combined product comprising one of: ZD6474 and 5-FU; ZD6474 and CPT-11; and ZD6474 and 5FU and CPT-11, for use in a method of therapy of a human or animal body; a kit comprising one of: ZD6474 and 5-FU; ZD6474 and CPT-11; and ZD6474 and 5-FU and CPT-11; for the use of one of: ZD6474 and 5-FU; ZD6474 and CPT-11; and ZD6474 and 5-FU and CPT-11, in the manufacture of a medicament for use in producing an antiangiogenic reducing effect and / or vascular permeability in a warm-blooded animal such as a human being optionally treated with ionizing radiation.

BR0407301-0A 2003-02-13 2004-02-11 Use of a combination, pharmaceutical composition, kit, and method for treating cancer in a warm-blooded animal such as a human. BRPI0407301A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0303289A GB0303289D0 (en) 2003-02-13 2003-02-13 Combination therapy
GB0314100A GB0314100D0 (en) 2003-06-18 2003-06-18 Combination therapy
GB0316184A GB0316184D0 (en) 2003-07-10 2003-07-10 Combination therapy
PCT/GB2004/000550 WO2004071397A2 (en) 2003-02-13 2004-02-11 Combination therapy of zd6474 with 5-fu or/and cpt-11

Publications (1)

Publication Number Publication Date
BRPI0407301A true BRPI0407301A (en) 2006-02-07

Family

ID=35745214

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407301-0A BRPI0407301A (en) 2003-02-13 2004-02-11 Use of a combination, pharmaceutical composition, kit, and method for treating cancer in a warm-blooded animal such as a human.

Country Status (1)

Country Link
BR (1) BRPI0407301A (en)

Similar Documents

Publication Publication Date Title
BR0315088A (en) Methods for producing an antiangiogenic and / or vascular permeability reducing effect in a warm-blooded animal and for treating cancer in a warm-blooded animal, pharmaceutical composition, kit, and use of zd6474 or an acceptable pharmaceutically acceptable salt thereof and gemcitabine
BR0213906A (en) Methods for producing an anti-angiogenic and / or vascular permeability reducing effect in a warm-blooded animal, and for treating cancer in a warm-blooded animal, pharmaceutical composition, kit, and use of zd6474 or one thereof pharmaceutically acceptable salt and a taxane
BR0313117A (en) Method for producing a vascular and / or antiangiogenic permeability reducing effect in a warm-blooded animal such as a human, method for treating cancer in a warm-blooded animal such as a human, pharmaceutical composition, kit, and , use of zd6474 or a pharmaceutically acceptable salt thereof and zd1839 or a pharmaceutically acceptable salt thereof
BRPI0412426A (en) use of zd6474 or a pharmaceutically acceptable salt thereof and a platinum antitumor agent, pharmaceutical composition, kit, and method for producing an antiangiogenic and / or vascular permeability reducing effect in a warm-blooded animal
BR0313116A (en) Method for producing a vascular and / or antiangiogenic permeability reducing effect on a warm-blooded animal such as a human, method for treating cancer in a warm-blooded animal such as a human, and use of zd6474 or a pharmaceutically acceptable salt thereof.
BRPI0516024A (en) use of azd 2171 or a pharmaceutically acceptable salt thereof and imatinib, pharmaceutical composition, kit, and method for producing an antiangiogenic effect and / or reducing vascular permeability in a warm-blooded animal
CY1111547T1 (en) COMBINATION ZD6474 AND PERMETRIC
BRPI0516052A (en) use of zd6474 or a pharmaceutically acceptable salt thereof and imatinib, pharmaceutical composition, kit, and method for producing an antiangiogenic effect and / or reducing vascular permeability in a warm-blooded animal
MXPA05008583A (en) Combination therapy of zd6474 with 5-fu or/and cpt-11.
BRPI0517953A (en) use of zd 6474, or a pharmaceutically acceptable salt thereof, and an antiandrogen, pharmaceutical composition, kit, and method for producing an effect of reducing vascular and / or antiangiogenic permeability in a warm-blooded animal
BRPI0412408A (en) methods for producing an antiangiogenic reducing effect and / or vascular permeability and for treating a cancer in a warm-blooded animal such as a human, pharmaceutical composition, kit, and use of azd2171 or a pharmaceutically acceptable salt thereof. and zd1839 or a pharmaceutically acceptable salt thereof.
BRPI0508982A (en) use of azd2171 or a pharmaceutically acceptable salt thereof excluding an azd2171 maleate salt, pharmaceutical composition, kit, method for treating a cancer in a warm-blooded animal such as a human, and use of azd2171 maleate salt azd2171 and 5 - fu and cpt - 11
BRPI0508959A (en) use of azd2171 or a pharmaceutically acceptable salt of the same, use of azd2171 maleate salt and oxaliplatin, pharmaceutical composition, kit, and method for producing an antiangiogenic effect and / or reducing vascular permeability in a warm-blooded animal
BRPI0412450A (en) methods for producing an antiangiogenic reducing and / or vascular permeability effect in a warm-blooded animal such as a human, and for treating a cancer, pharmaceutical composition, kit, and use of azd2171 or a pharmaceutically salt acceptable thereof and zd6126 or a pharmaceutically acceptable salt thereof
BRPI0508983A (en) use of azd2171 or a pharmaceutically acceptable salt thereof excluding an azd2171 maleate salt and a taxane, pharmaceutical composition, kit, and method for producing antiangiogenic effect and / or reducing vascular permeability in a warm-blooded animal such as as a human being
BRPI0407301A (en) Use of a combination, pharmaceutical composition, kit, and method for treating cancer in a warm-blooded animal such as a human.
BRPI0411567A (en) use of zd6126 or a pharmaceutically acceptable salt thereof and one of 5-fu, cpt-11, and 5-fu and cpt-11, pharmaceutical composition, kit, and methods for producing a vascular damage effect in an animal of warm blood and for the treatment of a cancer involving a solid tumor in a warm blooded animal
BR0317772A (en) Method of treating a behavioral disorder, use of a compound, and therapeutic agent for a behavioral disorder
ATE339209T1 (en) COMBINATION THERAPY WITH GEMZITABINE AND ZD6126

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.

B25B Requested transfer of rights rejected

Owner name: ASTRAZENECA AB (SE)